Aveta Biomics
Bedford, US · Founded 2013 · Delaware corporation
Aveta Biomics develops cancer therapeutics based on Orthologous Molecular Structures (OMS), metabolites from organisms with orthologous genes and processes, combined using an evolutionary-biology-based platform. Its drugs aim to treat and prevent cancers while addressing tumor heterogeneity and drug resistance.
Founders & leadership
PM
Parag MehtaExecutive
SM
Sharmila MudgalNamed on SEC filing
Board
SP
S. P. KothariBoard director
BT
Bharat TewarieBoard director
PD
Peter DolanBoard director
DP
David PageBoard director
Reported raises · per SEC filings
Form D private placements$6.2M disclosed across 3 rounds · 2018–2024
▶$4.5MraisedMar 2025 · 36 investors · PharmaceuticalsRule 506(b)
▶$4.5MraisedMar 2025 · 36 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- S. P. KothariDirector
- Parag MehtaExecutive Officer, Director
- Bharat TewarieDirector
- Peter DolanDirector
- David PageDirector
- Offering amount
- $8M
- Amount sold
- $4.5M
- First sale
- May 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$600KraisedFeb 2022 · 13 investors · BiotechnologyRule 506(b)
▶$600KraisedFeb 2022 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Parag MehtaExecutive Officer, Director
- Guha BalaDirector
- Bharat TewarieDirector
- Offering amount
- $5M
- Amount sold
- $600K
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.1MraisedMar 2018 · 4 investors · BiotechnologyRule 506(b)
▶$1.1MraisedMar 2018 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sharmila MudgalExecutive Officer, Director
- Parag MehtaExecutive Officer, Director
- SP KothariDirector
- Offering amount
- $2.5M
- Amount sold
- $1.1M
- First sale
- Mar 2018
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapBioworld9 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Doximity9 shared keywordsDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.
Companies competing with Aveta Biomics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Aveta Biomics do?
- Aveta Biomics develops cancer therapeutics based on Orthologous Molecular Structures (OMS), metabolites from organisms with orthologous genes and processes, combined using an evolutionary-biology-based platform. Its drugs aim to treat and prevent cancers while addressing tumor heterogeneity and drug resistance.
- How much funding has Aveta Biomics raised?
- Aveta Biomics has disclosed $6.2M raised across 3 rounds.
- Where is Aveta Biomics headquartered?
- Aveta Biomics is headquartered in Bedford, US.